A Phase 1 interventional study of Oxyntomodulin and Liraglutide 0.6 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to male participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2015-09-02.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 139th largest by enrollment, is one of 11 that started in 2011, is one of 25 in phase 1, and was the 28th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Mansa · Sites in United States
Ages 10+
Biolingus · Sites in Hong Kong
Ages 18–65
RenJi Hospital · Sites in China
Ages 18–65
University of Virginia · Sites in United States
Ages 21–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 64 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 46 · Phase 4 48
First in 1999; this study’s year is marked. 11 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 62 across the 151 interventional studies. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 151 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 162nd largest by enrollment of the 170 interventional ones that give a count, is one of 10 that started in 2011, is one of 55 in phase 1, and was the 118th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing liraglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03883412University of VirginiaEffect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, from their registry updates:
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a four-period crossover study to assess the glycemic effects of a single dose of oxyntomodulin (OXM) on the glucose levels in participants with Type 2 diabetes mellitus (T2DM). Participants were randomly assigned to 1 of 6 treatment sequences consisting of 4 treatment periods, with a 7-day wash-out between each treatment period. The primary hypothesis was that during graded glucose infusion (GGI) oxyntomodulin (OXM) is neutral or better than placebo (Pbo) at lowering ambient plasma glucose levels, and at significantly enhancing insulin secretion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Oxyntomodulin 3.0 pmol/kg/min in the first, Liraglutide 0.6 mg in the second, Placebo in the third, and Liraglutide 1.2 mg in the fourth period
Drug: Oxyntomodulin · Drug: Liraglutide 0.6 mg · Drug: Placebo for Oxyntomodulin · Drug: Placebo for Liraglutide
Participants received Liraglutide 0.6 mg in the first, Placebo in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Placebo in the fourth period
Drug: Oxyntomodulin · Drug: Liraglutide 0.6 mg · Drug: Placebo for Oxyntomodulin · Drug: Placebo for Liraglutide
Participants received Placebo in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
Drug: Oxyntomodulin · Drug: Liraglutide 0.6 mg · Drug: Placebo for Oxyntomodulin · Drug: Placebo for Liraglutide
Participants received Liraglutide 0.6 mg in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Placebo in the third and Liraglutide 1.2 mg in the fourth period
Drug: Oxyntomodulin · Drug: Liraglutide 0.6 mg · Drug: Liraglutide 1.2 mg · Drug: Placebo for Oxyntomodulin · Drug: Placebo for Liraglutide
Participants received Oxyntomodulin 3.0 pmol/kg/min in the first; Placebo in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
Drug: Oxyntomodulin · Drug: Liraglutide 0.6 mg · Drug: Placebo for Oxyntomodulin · Drug: Placebo for Liraglutide
Participants received Placebo in the first, Liraglutide 0.6 mg in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Liraglutide 1.2 mg in the fourth period
Drug: Oxyntomodulin · Drug: Liraglutide 0.6 mg · Drug: Liraglutide 1.2 mg · Drug: Placebo for Oxyntomodulin · Drug: Placebo for Liraglutide
3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)
Single subcutaneous dose in the evening of the day before the GGI (Day-1)
Also known as: Victoza®
Single subcutaneous dose in the evening of the day before the GGI (Day-1)
Also known as: Victoza®
IV infusion in the morning of the day of GGI (Day 1)
Single subcutaneous dose in the evening of the day before the GGI (Day-1)
Change From Baseline in Time-weighted Average of Glucose Measured by Area Under the Curve (AUC) After a Single Dose of Oxyntomodulin (OXM)
Participants received on Day (-1) an overnight intravenous (IV) infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of liraglutide (Lg) or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 OXM or placebo for OXM, accompanied by up to 160 minutes of graded glucose infusion (GGI). During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Glucose levels were measured from blood collected at baseline and during GGI at the following minutes: 0, 20, 40, 60, 80, 100, 120, 140, 160 and 165 in order to calculate the time-weighted average change from baseline in glucose AUC from 0-160 minutes.
Time frame: Baseline and during GGI at time points 0, 20, 40, 60, 80, 100, 120, 140, 160 and 165 minutes
Change From Baseline in Maximum Ambient Glucose Concentration (Gmax) After a Single Dose of OXM
Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of Lg or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 OXM or placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Glucose levels were measured from blood collected at baseline and during GGI to determine the maximum ambient glucose concentration above baseline.
Time frame: Baseline and up to 160 minutes after start of GGI
Change From Baseline in Beta Cell Sensitivity to Glucose (Φ) After a Single Dose of OXM
Beta cell sensitivity measures the ability to mount an insulin secretory response relative to the level of ambient plasma glucose. Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of Lg or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 a single dose of OXM or placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting 40 minutes. Glucose (G), insulin and C-peptide levels were measured from blood collected at baseline and during GGI, with the decay in C-peptide concentration used to indirectly estimate the Insulin Secretion Rate (ISR). Beta Cell Sensitivity (Φ) was determined from the regression of the ISR on ambient plasma glucose (G).
Time frame: Baseline and up to160 minutes after start of GGI
Change From Baseline in Insulinotrophic Effect (ISR/G) at the Highest Glucose Infusion Rate After Two Periods of Placebo Treatment
The reproducibility of insulinotrophic effects was compared after two separate placebo treatment periods within the same treatment sequence. Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single subcutaneous dose of placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Over these two treatment periods glucose (G), insulin and C-peptide levels were measured from blood collected at the highest glucose infusion rate; with the decay in C-peptide concentration used to indirectly estimate the Insulin Secretion Rate (ISR), and hence to determine the insulinotrophic effect, ISR/G.
Time frame: Baseline and 160 minutes after start of GGI at each placebo treatment period
Change From Baseline in Gmax After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM
Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of Lg or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 a single dose of OXM or placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Glucose levels were measured from blood collected at baseline and during GGI to determine the maximum ambient glucose concentration above baseline.
Time frame: Baseline and up to 160 minutes after start of GGI
Change From Baseline in Insulinotrophic Effect (ISR/G) After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM
Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of Lg or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 a single dose of OXM or placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Glucose (G), insulin and C-peptide levels were measured from blood collected at baseline and during GGI; with the decay in C-peptide concentration used to indirectly estimate the Insulin Secretion Rate (ISR) and hence determine ISR/G.
Time frame: Baseline and up to 160 minutes after start of GGI
| Milestone | OXM --> Lg-0.6--> Pbo--> Lg-1.2 | Lg-0.6 mg--> Pbo--> OXM--> Pbo | Pbo--> OXM--> Lg-0.6-->Pbo | Lg-0.6--> OXM--> Pbo--> Lg-1.2 | OXM--> Pbo--> Lg-0.6--> Pbo | Pbo--> Lg-0.6--> OXM--> Lg-1.2 |
|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | OXM --> Lg-0.6--> Pbo--> Lg-1.2 | Lg-0.6 mg--> Pbo--> OXM--> Pbo | Pbo--> OXM--> Lg-0.6-->Pbo | Lg-0.6--> OXM--> Pbo--> Lg-1.2 | OXM--> Pbo--> Lg-0.6--> Pbo | Pbo--> Lg-0.6--> OXM--> Lg-1.2 |
|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | OXM --> Lg-0.6--> Pbo--> Lg-1.2 | Lg-0.6 mg--> Pbo--> OXM--> Pbo | Pbo--> OXM--> Lg-0.6-->Pbo | Lg-0.6--> OXM--> Pbo--> Lg-1.2 | OXM--> Pbo--> Lg-0.6--> Pbo | Pbo--> Lg-0.6--> OXM--> Lg-1.2 |
|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | OXM --> Lg-0.6--> Pbo--> Lg-1.2 | Lg-0.6 mg--> Pbo--> OXM--> Pbo | Pbo--> OXM--> Lg-0.6-->Pbo | Lg-0.6--> OXM--> Pbo--> Lg-1.2 | OXM--> Pbo--> Lg-0.6--> Pbo | Pbo--> Lg-0.6--> OXM--> Lg-1.2 |
|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | OXM --> Lg-0.6--> Pbo--> Lg-1.2 | Lg-0.6 mg--> Pbo--> OXM--> Pbo | Pbo--> OXM--> Lg-0.6-->Pbo | Lg-0.6--> OXM--> Pbo--> Lg-1.2 | OXM--> Pbo--> Lg-0.6--> Pbo | Pbo--> Lg-0.6--> OXM--> Lg-1.2 |
|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | OXM --> Lg-0.6--> Pbo--> Lg-1.2 | Lg-0.6 mg--> Pbo--> OXM--> Pbo | Pbo--> OXM--> Lg-0.6-->Pbo | Lg-0.6--> OXM--> Pbo--> Lg-1.2 | OXM--> Pbo--> Lg-0.6--> Pbo | Pbo--> Lg-0.6--> OXM--> Lg-1.2 |
|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | OXM --> Lg-0.6--> Pbo--> Lg-1.2 | Lg-0.6 mg--> Pbo--> OXM--> Pbo | Pbo--> OXM--> Lg-0.6-->Pbo | Lg-0.6--> OXM--> Pbo--> Lg-1.2 | OXM--> Pbo--> Lg-0.6--> Pbo | Pbo--> Lg-0.6--> OXM--> Lg-1.2 |
|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Participants received on Day (-1) an overnight intravenous (IV) infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of liraglutide (Lg) or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 OXM or placebo for OXM, accompanied by up to 160 minutes of graded glucose infusion (GGI). During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Glucose levels were measured from blood collected at baseline and during GGI at the following minutes: 0, 20, 40, 60, 80, 100, 120, 140, 160 and 165 in order to calculate the time-weighted average change from baseline in glucose AUC from 0-160 minutes.
| mg/dL | Oxyntomodulin | Placebo |
|---|---|---|
| Change From Baseline in Time-weighted Average of Glucose Measured by Area Under the Curve (AUC) After a Single Dose of Oxyntomodulin (OXM) | 106.3 ± 23.03 | 122.6 ± 35.29 |
Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of Lg or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 OXM or placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Glucose levels were measured from blood collected at baseline and during GGI to determine the maximum ambient glucose concentration above baseline.
| mg/dL | Oxyntomodulin | Placebo |
|---|---|---|
| Change From Baseline in Maximum Ambient Glucose Concentration (Gmax) After a Single Dose of OXM | 211.0 ± 63.00 | 272.9 ± 50.05 |
Beta cell sensitivity measures the ability to mount an insulin secretory response relative to the level of ambient plasma glucose. Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of Lg or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 a single dose of OXM or placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting 40 minutes. Glucose (G), insulin and C-peptide levels were measured from blood collected at baseline and during GGI, with the decay in C-peptide concentration used to indirectly estimate the Insulin Secretion Rate (ISR). Beta Cell Sensitivity (Φ) was determined from the regression of the ISR on ambient plasma glucose (G).
| ISR (ng/mL) / Glucose (mg/dL) | Oxyntomodulin | Placebo |
|---|---|---|
| Change From Baseline in Beta Cell Sensitivity to Glucose (Φ) After a Single Dose of OXM | 0.019 ± 0.010 | 0.006 ± 0.003 |
The reproducibility of insulinotrophic effects was compared after two separate placebo treatment periods within the same treatment sequence. Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single subcutaneous dose of placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Over these two treatment periods glucose (G), insulin and C-peptide levels were measured from blood collected at the highest glucose infusion rate; with the decay in C-peptide concentration used to indirectly estimate the Insulin Secretion Rate (ISR), and hence to determine the insulinotrophic effect, ISR/G.
| ISR (ng/mg) / Glucose (mg/dL) | Placebo Period 1 | Placebo Period 2 |
|---|---|---|
| Change From Baseline in Insulinotrophic Effect (ISR/G) at the Highest Glucose Infusion Rate After Two Periods of Placebo Treatment | 0.0075 ± 0.0031 | 0.0070 ± 0.0027 |
Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of Lg or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 a single dose of OXM or placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Glucose levels were measured from blood collected at baseline and during GGI to determine the maximum ambient glucose concentration above baseline.
| mg/dL | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Oxyntomodulin | Placebo |
|---|---|---|---|---|
| Change From Baseline in Gmax After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM | 209.7 ± 66.08 | 157.9 ± 93.36 | 211.0 ± 63.00 | 272.9 ± 50.05 |
Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of Lg or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 a single dose of OXM or placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Glucose (G), insulin and C-peptide levels were measured from blood collected at baseline and during GGI; with the decay in C-peptide concentration used to indirectly estimate the Insulin Secretion Rate (ISR) and hence determine ISR/G.
| ISR (ng/min) / Glucose (mg/dL) | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Oxyntomodulin | Placebo |
|---|---|---|---|---|
| Change From Baseline in Insulinotrophic Effect (ISR/G) After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM | 0.026 ± 0.015 | 0.035 ± 0.018 | 0.019 ± 0.010 | 0.006 ± 0.003 |
Collected over Up to 14 days after last dose of study medication. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oxyntomodulin | — | 0/12 (0%) | 6/12 (50%) |
| Liraglutide 0.6 mg | — | 0/12 (0%) | 7/12 (58.3%) |
| Liraglutide 1.2 mg | — | 0/6 (0%) | 1/6 (16.7%) |
| Placebo | — | 0/12 (0%) | 8/12 (66.7%) |
| Event | Oxyntomodulin | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Placebo |
|---|---|---|---|---|
| HeadacheNervous system disorders | 2/12 | 4/12 | 0/6 | 3/12 |
| FatigueGeneral disorders | 2/12 | 3/12 | 0/6 | 1/12 |
| Catheter Site PainGeneral disorders | 0/12 | 0/12 | 1/6 | 1/12 |
| Catheter Site Related ReactionGeneral disorders | 1/12 | 0/12 | 0/6 | 2/12 |
| Dry MouthGastrointestinal disorders | 0/12 | 1/12 | 0/6 | 1/12 |
| NauseaGastrointestinal disorders | 0/12 | 0/12 | 0/6 | 1/12 |
| Salivary HypersecretionGastrointestinal disorders | 0/12 | 0/12 | 0/6 | 1/12 |
| Oedema PeripheralGeneral disorders | 1/12 | 0/12 | 0/6 | 0/12 |
| RhinitisInfections and infestations | 1/12 | 0/12 | 0/6 | 0/12 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/12 | 0/12 | 0/6 | 1/12 |
| Age, Continuous(years) | All Treated Participants |
|---|---|
| Mean | 58.8 ± 3.8 |
| Sex: Female, Male(Participants) | All Treated Participants |
|---|---|
| Female | 0 |
| Male | 12 |
No study locations are listed for this record.
The record gives a start of Jun 2011, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide